For: | Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases 2013; 1(2): 74-78 [PMID: 24303470 DOI: 10.12998/wjcc.v1.i2.74] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v1/i2/74.htm |
Number | Citing Articles |
1 |
M. M. Kudishina, I. V. Kozlova, E. A. Yavaeva. Skin manifestations of inflammatory bowel diseases. Experimental and Clinical Gastroenterology 2020; (3): 113 doi: 10.31146/1682-8658-ecg-175-3-113-117
|
2 |
Wenjuan Chen, Hui Xu, Xiuxiu Wang, Junying Gu, Huizi Xiong, Yuling Shi. The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis. International Immunopharmacology 2015; 28(1): 146 doi: 10.1016/j.intimp.2015.05.049
|
3 |
Masashi Ohno, Shigeki Koyama, Mariko Ohara, Kazumi Shimamoto, Yu Kobayashi, Fumiyasu Nakamura, Kazuki Mitsuru, Akira Andoh. Pyoderma Gangrenosum with Ulcerative Colitis Successfully Treated by the Combination of Granulocyte and Monocyte Adsorption Apheresis and Corticosteroids. Internal Medicine 2016; 55(1): 25 doi: 10.2169/internalmedicine.55.5422
|
4 |
Sven R. Quist, Luise Kraas. Therapieoptionen beim Pyoderma gangraenosum. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2017; 15(1): 34 doi: 10.1111/ddg.13173_g
|
5 |
Mark Fleisher, Jan Marsal, Scott D. Lee, Laura E. Frado, Alyssa Parian, Burton I. Korelitz, Brian G. Feagan. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Digestive Diseases and Sciences 2018; 63(4): 825 doi: 10.1007/s10620-018-4971-1
|
6 |
Mauro Mastronardi, Elisabetta Cavalcanti, Nunzia Labarile, Raffaele Armentano, Francesco Gabriele, Margherita Curlo. Pyoderma gangrenosum in ulcerative colitis patient treated with vedolizumab: adsorptive granulocyte/monocyte apheresis as a new therapeutic option refractory cases – a case report and literature review. Therapeutic Advances in Chronic Disease 2023; 14 doi: 10.1177/20406223231194190
|
7 |
Ho D. Na, Hongfei Yan, Chul H. Park. Misdiagnosis of Pyoderma Gangrenosum Increases Medical Costs and Prolongs Hospital Stay: A Case Report. The International Journal of Lower Extremity Wounds 2023; 22(2): 428 doi: 10.1177/15347346211011870
|
8 |
Kentaro Tominaga, Kenya Kamimura, Hiroki Sato, Masayoshi Ko, Yuzo Kawata, Takeshi Mizusawa, Junji Yokoyama, Shuji Terai. Cytapheresis for pyoderma gangrenosum associated with inflammatory bowel disease: A review of current status. World Journal of Clinical Cases 2020; 8(11): 2092-2101 doi: 10.12998/wjcc.v8.i11.2092
|
9 |
Sven R. Quist, Luise Kraas. Treatment options for pyoderma gangrenosum. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2017; 15(1): 34 doi: 10.1111/ddg.13173
|
10 |
Tomoyoshi Shibuya, Keiichi Haga, Michio Saeki, Mayuko Haraikawa, Hitoshi Tsuchihashi, Koki Okahara, Osamu Nomura, Hirofumi Fukushima, Takashi Murakami, Dai Ishikawa, Shigaku Ikeda, Akihito Nagahara. Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresis. Journal of Clinical Apheresis 2020; 35(5): 488 doi: 10.1002/jca.21821
|
11 |
Smaranda Diaconescu, Silvia Strat, Gheorghe G. Balan, Carmen Anton, Gabriela Stefanescu, Ileana Ioniuc, Ana Maria Alexandra Stanescu. Dermatological Manifestations in Pediatric Inflammatory Bowel Disease. Medicina 2020; 56(9): 425 doi: 10.3390/medicina56090425
|
12 |
Anastasia Atanasova Chokoeva, José Carlos Cardoso, Uwe Wollina, Georgi Tchernev. Pyoderma gangrenosum—a novel approach?. Wiener Medizinische Wochenschrift 2017; 167(3-4): 58 doi: 10.1007/s10354-016-0472-z
|
13 |
Ignacio Marin-Jimenez, Guillermo Bastida, Ana Forés, Esther Garcia-Planella, Federico Argüelles-Arias, Pilar Sarasa, Ignacio Tagarro, Alonso Fernández-Nistal, Carmen Montoto, Mariam Aguas, Javier Santos-Fernández, Marta Maia Bosca-Watts, Rocio Ferreiro, Olga Merino, Xavier Aldeguer, Xavier Cortés, Beatriz Sicilia, Francisco Mesonero, Manuel Barreiro-de Acosta. Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study. BMJ Open Gastroenterology 2020; 7(1): e000351 doi: 10.1136/bmjgast-2019-000351
|
14 |
Rafael Luís Luporini, Pâmela Cristina Bellaz Do Amaral Campos Silva, Miguel Regueiro. Hidradenitis suppurativa: Coexistence or dermatological extraintestinal manifestation of Crohn's disease?. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1151370
|
15 |
Jia-Huei Zheng, Shian-Ren Lin, Feng-Jen Tseng, May-Jywan Tsai, Sheng-I Lue, Yi-Chen Chia, Mindar Woon, Yaw-Syan Fu, Ching-Feng Weng. Clerodane Diterpene Ameliorates Inflammatory Bowel Disease and Potentiates Cell Apoptosis of Colorectal Cancer. Biomolecules 2019; 9(12): 762 doi: 10.3390/biom9120762
|
16 |
Ripalta Colìa, Addolorata Corrado, Francesco Paolo Cantatore. Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases. Annals of Medicine 2016; 48(8): 577 doi: 10.1080/07853890.2016.1195011
|
17 |
Eva Remenyik. European Handbook of Dermatological Treatments. 2023; : 297 doi: 10.1007/978-3-031-15130-9_27
|
18 |
Akiko Arimura, Miho Hatanaka, Hiromi Katsue, Shigeto Matsushita, Takuro Kanekura. Granulocyte and monocyte adsorption apheresis for paradoxical reaction to infliximab. The Journal of Dermatology 2015; 42(4): 438 doi: 10.1111/1346-8138.12789
|
19 |
R. E. Faulkes. Upper limb erythema nodosum: the first presentation of Crohn's disease. Clinical Case Reports 2014; 2(5): 183 doi: 10.1002/ccr3.87
|
20 |
Lisa Younge. Dermatological complications to consider when managing IBD patients. Gastrointestinal Nursing 2015; 13(4): 34 doi: 10.12968/gasn.2015.13.4.34
|
21 |
Laurent Peyrin-Biroulet, Gert Van Assche, David Gómez-Ulloa, Laura García-Álvarez, Núria Lara, Chris M. Black, Sumesh Kachroo. Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2017; 15(1): 25 doi: 10.1016/j.cgh.2016.06.025
|